Trial | NCT03044964  Report issue

Title

Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR)
Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Unknown status

  • Intervention/Treatment

    ranolazine ...

  • Study Participants

    40
The post-marketing study is designed to evaluate the activity level and exercise tolerance of patients with deferred percutaneous intervention due to FFR (fractional flow reserve) greater or equal to 0.81 and treatment with Ranolazine versus placebo.
Ranolazine was approved as Ranexa in the United States on January 31, 2006 for the treatment of chronic angina. This post-marketing study is a single-center, double-blind, prospective, randomized, parallel-group evaluation of patients randomized 1:1 between Ranolazine and placebo.
Study Started
Jan 10
2017
Primary Completion
Oct 31
2017
Anticipated
Study Completion
Oct 31
2017
Anticipated
Last Update
Feb 07
2017
Estimate

Drug Ranolazine

Patients will be started on 500mg twice daily and may be increased to 1000mg twice daily after 1 week. Patients will or may remain on the 1000mg for 5 weeks.

  • Other names: Ranexa

Drug Placebo

Patients will be started on 500mg twice daily and may be increased to 1000mg twice daily after 1 week. Patients will or may remain on the 1000mg for 5 weeks.

Ranolazine Active Comparator

At randomization, patients will be started on 500mg of Ranolazine, twice daily for 1 week. After 1 week, the dosage may be increased to 1000mg of Ranolazine, twice daily for 5 weeks.

Placebo Placebo Comparator

At Randomization, patients will be started on 500mg of a placebo, twice daily for 1 week. After 1 week, the dosage of the placebo may be increased to 1000mg, twice daily for 5 weeks.

Criteria 

Inclusion Criteria:

Subjects must be willing and able to comply with schedules visits, treatment plan, and other study procedures.
There must be evidence of personally signed and dated informed consent documents.
Subjects must have a documented history of anginal chest pain equal to or greater than one (1) episode per week prior to cardiac catheterization.
Subjects must have greater than or equal to one (1) episode of angina chest pain between screening visit and randomization visit.

Subject must have documented cardiac catheterization with deferred percutaneous intervention and fractional flow reserve (FFR) greater than or equal to 0.81 within thirty (30) days, or an (FFR) less than 0.81if not a candidate for revascularization based upon operator discretion.

-

Exclusion Criteria:

Subjects with a congenital or acquired QT interval prolongation (greater than or equal to 440ms in men/greater than or equal to 460ms in women).
Subjects prescibed strong CYP3A inhibitors (including ketaconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir and saquinavir.) and/or strong CYP3A inducers (rifampin, rifabutin, rifapentin, Phenobarbital, phenytoin, carbamezepine and St. John's wort).
Subjects prescribed to Simvastatin (Zocor) that cannot have dose reduced to appropriate levels (20mg QD) per physician or have medication discontinued during the clinical trial.
Subjects prescribed Metformin that cannot have dose reduced to appropriate levels (less than or equal to 850mg BID) per physician or have medication discontinued during the clinical trial.
Subjects prescribed Digoxin that cannot have dose reduced to appropriate levels (0.125mg QD) per physician or have medication discontinued during the clinical trial.
Subjects with life expectancy less than the duration of the trial.
Subjects with a history of liver cirrhosis.
Subject with chronic renal disease with creatinine clearance of less than 30mL/min.
Subjects participating in any other clinical trial for the duration of the trial.
Females who are of childbearing potential, who are unwilling or unable to use highly effective method of contraception -
No Results Posted